Radiopharm Theranostics Ltd ADR RADX 深 滬
已收盤 08-29 16:00:00 美东时间
5.49
-0.210
-3.68%
華盛通- 最 高5.74
- 今 開5.74
- 成交量 6872股
- 最 低 5.49
- 昨 收 5.70
- 總市值 4271.17万
- 52周最高 50.82
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.4962
- 委 比 -48.72%
- 總股本 777.99万
- 歷史最高 50.82
- 量 比 0.50
- 振 幅 4.39%
- 歷史最低 3.4962
- 每 手 1
- 風險率 1.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Radiopharm Theranostics Sees Revenue Surge Despite Continued Losses
An update from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. ...
08-29 14:25
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
Radiopharm Theranostics announced financial results for FY2025 and provided updates on its pipeline. Key highlights include: - On track to complete enrollment of first two cohorts for RAD204 at 60mCi dose. - Initiated Phase 1 HEAT trial for RAD202 targeting HER2-positive tumors. - FDA granted Fast Track Designation for RAD101 to assess brain metastases. - Secured supply agreements for key radioisotopes and expanded clinical trials. - Y...
07-29 11:30
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Radiopharm Theranostics announced FDA clearance for their IND application for Betabart (RV-01), a Lu177-B7-H3 monoclonal antibody targeting the 4Ig isoform of B7H3 highly expressed in tumors. RV-01 is set to begin its first-in-human Phase 1 clinical trial in solid tumors in Q4 2025. The antibody's liver clearance, shortened half-life, and strong affinity for the target may offer advantages over other therapies. The company plans to dose the first...
07-28 12:00
Brookline Capital Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $18
Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and announces Price Target of $18.
07-21 20:33
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
Radiopharm Theranostics has signed a supply agreement with Cyclotek to produce RAD 402, a放射性药物 for prostate cancer treatment, labeled with Terbium-161. The Phase 1 clinical trial, supported by this agreement, is expected to begin in the second half of 2025. RAD 402 targets KLK3, with potential improved therapeutic efficacy compared to existing treatments. This collaboration aims to bring an innovative treatment option to prostate cancer patients.
06-24 12:00
Radiopharm Theranostics Advances Prostate Cancer Trial with Cyclotek Partnership
An announcement from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now avail...
06-24 09:17
Radiopharm Theranostics Announces Change in Substantial Holder Interests
The latest update is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Ra...
06-16 15:18
Radiopharm Theranostics Issues New Shares, Ensures Compliance
Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Ra...
06-12 07:27
Radiopharm Theranostics' RAD101 Receives FDA Fast Track Designation For Imaging Brain Metastases
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
06-11 20:10
Radiopharm Theranostics Announces New Securities Issue
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an announcement. Rad...
06-10 15:48
